{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:09:13Z","timestamp":1761894553402,"version":"build-2065373602"},"reference-count":76,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T00:00:00Z","timestamp":1570665600000},"content-version":"vor","delay-in-days":4331,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1016\/j.breast.2007.05.008","type":"journal-article","created":{"date-parts":[[2007,7,3]],"date-time":"2007-07-03T07:21:07Z","timestamp":1183447267000},"page":"615-624","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Comparative evaluation of non-informative HER-2 immunoreactions (2+) in breast carcinomas with FISH, CISH and QRT-PCR"],"prefix":"10.1016","volume":"16","author":[{"given":"Evanthia","family":"Kostopoulou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitra","family":"Vageli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Despina","family":"Kaisaridou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianna","family":"Nakou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Netsika","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Vladica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandros","family":"Daponte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Koukoulis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2007.05.008_bib1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/01.MP.0000052102.90815.82","article-title":"Current perspectives on HER2 testing: a review of national testing guidelines","volume":"16","author":"Bilous","year":"2003","journal-title":"Mod Pathol"},{"key":"10.1016\/j.breast.2007.05.008_bib2","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1074\/mcp.R400001-MCP200","article-title":"Targeted therapy in breast cancer: the HER-2\/neu gene and protein","volume":"3","author":"Ross","year":"2004","journal-title":"Mol Cel Proteom"},{"key":"10.1016\/j.breast.2007.05.008_bib3","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/00313020120083133","article-title":"HER2 Testing Advisory Board. HER2 testing recommendations in Australia","volume":"33","author":"Bilous","year":"2001","journal-title":"Pathology"},{"key":"10.1016\/j.breast.2007.05.008_bib4","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.humpath.2004.11.010","article-title":"Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines","volume":"36","author":"Hicks","year":"2005","journal-title":"Hum Pathol"},{"key":"10.1016\/j.breast.2007.05.008_bib5","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0025-6196(11)62329-X","article-title":"HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization","volume":"77","author":"Perez","year":"2002","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.breast.2007.05.008_bib6","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1200\/JCO.2000.18.21.3651","article-title":"Assessment of methods for tissue-based detection of the HER-2\/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry","volume":"18","author":"Pauletti","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2007.05.008_bib7","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.2002.09.094","article-title":"Evaluation of HER-2\/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens","volume":"20","author":"Press","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2007.05.008_bib8","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1365-2559.2004.01903.x","article-title":"Testing for HER2 in breast cancer","volume":"45","author":"Lewis","year":"2004","journal-title":"Histopathology"},{"key":"10.1016\/j.breast.2007.05.008_bib9","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1046\/j.1365-2559.2003.01598.x","article-title":"Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French Multicentre GEFPICS Study","volume":"42","author":"Vincent-Salomon","year":"2003","journal-title":"Histopathology"},{"key":"10.1016\/j.breast.2007.05.008_bib10","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1001\/jama.291.16.1972","article-title":"HER-2 testing in breast cancer using parallel tissue-based methods","volume":"291","author":"Yaziji","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.breast.2007.05.008_bib11","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1200\/JCO.2005.11.012","article-title":"Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients","volume":"23","author":"Dressler","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2007.05.008_bib12","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/jcp.2003.009308","article-title":"Guidelines for HER2 testing in the UK","volume":"57","author":"Hsi","year":"2004","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.breast.2007.05.008_bib13","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S1470-2045(02)00676-9","article-title":"Trastuzumab: hopes and realities","volume":"3","author":"Leyland-Jones","year":"2002","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2007.05.008_bib14","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/annonc\/mdi326","article-title":"Meeting highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005","volume":"16","author":"Goldhirsch","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2007.05.008_bib15","first-page":"349","article-title":"Review: significance of, and optimal screening for, HER-2 gene amplification and protein overexpression in breast carcinoma","volume":"31","author":"Funkhouser","year":"2001","journal-title":"Ann Clin Lab Sci"},{"key":"10.1016\/j.breast.2007.05.008_bib16","first-page":"4679","article-title":"Real-time RT-PCR: a complementary method to detect HER-2 status in breast carcinoma","volume":"25","author":"Bossard","year":"2005","journal-title":"Anticancer Res"},{"key":"10.1016\/j.breast.2007.05.008_bib17","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1365-2559.2005.02112.x","article-title":"Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2\/neu overexpression in human breast carcinomas","volume":"46","author":"Vanden Bempt","year":"2005","journal-title":"Histopathology"},{"key":"10.1016\/j.breast.2007.05.008_bib18","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1177\/172460080401900203","article-title":"Gene transcript assay by real-time RT-PCR in epithelial breast cancer cells selected by laser microdissection","volume":"19","author":"Becette","year":"2004","journal-title":"Int J Biol Markers"},{"key":"10.1016\/j.breast.2007.05.008_bib19","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1078\/0344-0338-00445","article-title":"Relative quantification of ERBB2 mRNA in invasive duct carcinoma of the breast: correlation with ERBB-2 protein expression and ERBB2 gene copy number","volume":"199","author":"Mrhalova","year":"2003","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.breast.2007.05.008_bib20","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1309\/8A2DJFT07NE6EWHE","article-title":"Detection and quantitation of HER-2 gene amplification and protein expression in breast carcinoma","volume":"122","author":"Bofin","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.breast.2007.05.008_bib21","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/path.1523","article-title":"Comparative multi-methodological measurement of ERBB2 status in breast cancer","volume":"202","author":"Ginestier","year":"2004","journal-title":"J Pathol"},{"key":"10.1016\/j.breast.2007.05.008_bib22","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1093\/clinchem\/45.8.1148","article-title":"Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications","volume":"45","author":"Bieche","year":"1999","journal-title":"Clin Chem"},{"key":"10.1016\/j.breast.2007.05.008_bib23","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/ijc.11273","article-title":"Prognostic value of ERBB family mRNA expression in breast carcinomas","volume":"106","author":"Bieche","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.breast.2007.05.008_bib24","doi-asserted-by":"crossref","first-page":"8348","DOI":"10.1158\/1078-0432.CCR-05-0841","article-title":"Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization","volume":"11","author":"Vinatzer","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.breast.2007.05.008_bib25","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1177\/172460080602100105","article-title":"Simultaneous quantitative detection of relevant biomarkers in breast cancer by quantitative real-time PCR","volume":"21","author":"Labuhn","year":"2006","journal-title":"Int J Biol Markers"},{"key":"10.1016\/j.breast.2007.05.008_bib26","first-page":"212","article-title":"A real-time one-step reverse transcriptase-polymerase chain reaction method to quantify c-erbB-2 expression in human breast cancer","volume":"24","author":"Pawlowski","year":"2000","journal-title":"Cancer Detect Prev"},{"key":"10.1016\/j.breast.2007.05.008_bib27","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1267\/ahc.37.73","article-title":"Comparison of HER2 mRNA amplification with immunohistochemistry in human breast cancer using laser assisted microdissection technique","volume":"37","author":"Nakanishi","year":"2004","journal-title":"Acta Histochem Cytochem"},{"key":"10.1016\/j.breast.2007.05.008_bib28","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1525-1578(10)60490-4","article-title":"Real-time quantitative PCR of microdissected paraffin-embedded breast carcinoma\u2014an alternative method for her-2\/neu analysis","volume":"6","author":"Gjerdrum","year":"2004","journal-title":"J Molec Diagn"},{"key":"10.1016\/j.breast.2007.05.008_bib29","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/01.pap.0000213043.16200.92","article-title":"Controversies in the assessment of HER-2. More questions than answers","volume":"13","author":"Leong","year":"2006","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.breast.2007.05.008_bib30","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1309\/J9VXABUGKC4Y07DL","article-title":"Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining","volume":"124","author":"Lewis","year":"2005","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.breast.2007.05.008_bib31","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1200\/JCO.2001.19.10.2714","article-title":"Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message","volume":"19","author":"Tubbs","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2007.05.008_bib32","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1309\/VE7862V2646BR6EX","article-title":"HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2279 cases and comparison of dual-color and single-color scoring","volume":"121","author":"Lal","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.breast.2007.05.008_bib33","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S0960-9776(02)00273-4","article-title":"Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancers as part of the HER2000 International Study","volume":"12","author":"Bilous","year":"2003","journal-title":"Breast"},{"key":"10.1016\/j.breast.2007.05.008_bib34","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/jcp.2003.007724","article-title":"Best Practice No 176: updated recommendations for HER2 testing in the UK","volume":"57","author":"Ellis","year":"2004","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.breast.2007.05.008_bib35","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1309\/FUQH92B039025LHG","article-title":"Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay","volume":"121","author":"Varshney","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.breast.2007.05.008_bib36","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.clon.2005.06.010","article-title":"High efficacy of gemcitabine and cisplatin plus trastuzumab in patients with HER2-overexpressing metastatic breast cancer: a phase II study","volume":"17","author":"Stemmler","year":"2005","journal-title":"Clin Oncol"},{"key":"10.1016\/j.breast.2007.05.008_bib37","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1200\/JCO.2001.19.10.2587","article-title":"Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification","volume":"19","author":"Seidman","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2007.05.008_bib38","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1200\/JCO.1999.17.9.2639","article-title":"Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease","volume":"17","author":"Cobleigh","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2007.05.008_bib39","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000055405","article-title":"The predictive value of HER2 in breast cancer","volume":"61","author":"Piccart","year":"2001","journal-title":"Oncology"},{"key":"10.1016\/j.breast.2007.05.008_bib40","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10549-005-9136-1","article-title":"Pathology of borderline HER-2\/neu breast carcinoma: a biologically distinct phenotype","volume":"98","author":"Killeen","year":"2006","journal-title":"Breast Cancer Res Tr"},{"key":"10.1016\/j.breast.2007.05.008_bib41","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1309\/Q0DGL26RUCK1K5EV","article-title":"Comparison of immunohistochemical and fluorescence in situ hibridization assessement of HER-2 status in routine practise","volume":"123","author":"Dolan","year":"2005","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.breast.2007.05.008_bib42","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1309\/R2X4KK22QCL7PLME","article-title":"c-erb-b2 amplification by fluorescence in situ hybridization in breast cancer specimens read as 2+ in immunohistochemical analysis","volume":"124","author":"Lan","year":"2005","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.breast.2007.05.008_bib43","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.ejca.2006.03.011","article-title":"Analysis of aneusomy level and HER-2 gene copy number and their effect on amplification rate in breast cancer specimens read as 2+ in immunohistochemical analysis","volume":"42","author":"Merola","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.breast.2007.05.008_bib44","doi-asserted-by":"crossref","first-page":"R267","DOI":"10.1186\/bcr996","article-title":"Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hibridization and immunohistochemistry","volume":"7","author":"Salido","year":"2005","journal-title":"Breast Cancer Res"},{"issue":"Suppl 1","key":"10.1016\/j.breast.2007.05.008_bib45","first-page":"57A","article-title":"Frequency of indeterminate HER-2\/neu staining and gene amplification in ductal and lobular carcinoma: a comparative study","volume":"18","author":"Zhang","year":"2005","journal-title":"Mod Pathol"},{"key":"10.1016\/j.breast.2007.05.008_bib46","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10549-004-6275-8","article-title":"Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab","volume":"93","author":"Dybdal","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2007.05.008_bib47","first-page":"227","article-title":"HER-2 status determination in breast carcinomas. A practical approach","volume":"21","author":"Garcia-Cabalero","year":"2006","journal-title":"Histol Histopathol"},{"key":"10.1016\/j.breast.2007.05.008_bib48","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1046\/j.1524-4741.2001.21018.x","article-title":"Her-2\/neu gene amplification in low to moderately expressing breast cancers: possible role of chromosome 17\/Her-2\/neu polysomy","volume":"7","author":"Bose","year":"2001","journal-title":"Breast J"},{"key":"10.1016\/j.breast.2007.05.008_bib49","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1046\/j.1440-1827.2001.01255.x","article-title":"Chromogenic in situ hybridization analysis of HER-2\/neu status in breast carcinoma: application in screening of patients for trastuzumab (Herceptin) therapy","volume":"51","author":"Kumamoto","year":"2001","journal-title":"Pathol Int"},{"key":"10.1016\/j.breast.2007.05.008_bib50","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1046\/j.1365-2559.2000.00984.x","article-title":"Comparative methodological analysis of erbB-2\/HER-2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use","volume":"37","author":"Bankfalvi","year":"2000","journal-title":"Histopathology"},{"key":"10.1016\/j.breast.2007.05.008_bib51","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ijc.2910640502","article-title":"ERBB2 gene amplification detected by fluorescent differential polymerase chain reaction in paraffin-embedded breast carcinoma tissues","volume":"64","author":"An","year":"1995","journal-title":"Int J Cancer"},{"year":"1987","series-title":"Immunohistology and electron microscopy of anaplastic and pleomorphic tumors","author":"Leong","key":"10.1016\/j.breast.2007.05.008_bib52"},{"key":"10.1016\/j.breast.2007.05.008_bib53","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1038\/sj.bjc.6600943","article-title":"Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer","volume":"88","author":"Arnould","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.breast.2007.05.008_bib54","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1525-1578(10)60467-9","article-title":"Impact of polysomy 17 on HER-2\/neu immunohistochemistry in breast carcinomas without HER-2\/neu gene amplification","volume":"5","author":"Lal","year":"2003","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.breast.2007.05.008_bib55","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1158\/1078-0432.CCR-04-2256","article-title":"Polysomy 17 in HER-2\/neu status elaboration in breast cancer: effect on daily practice","volume":"11","author":"Ma","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2007.05.008_bib56","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/01.pai.0000132189.01233.6d","article-title":"HER2 positivity in breast carcinoma: a comparison of chromogenic in situ hybridization with fluorescence in situ hybridization in tissue microarrays, with targeted evaluation of intratumoral heterogeneity by in situ hybridization","volume":"13","author":"Loring","year":"2005","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.breast.2007.05.008_bib57","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/1066896906293055","article-title":"Intratumoral heterogenity of HER-2\/neu in invasive mammary carcinomas using fluorescence in-situ hybridization and tissue microarray","volume":"14","author":"Shin","year":"2006","journal-title":"Int J Surg Pathol"},{"key":"10.1016\/j.breast.2007.05.008_bib58","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1046\/j.1524-4741.1999.97088.x","article-title":"Marked intratumoral heterogeneity of the proto-oncogene Her-2\/neu determined by three different detection systems","volume":"5","author":"Pertschuk","year":"1999","journal-title":"Breast J"},{"key":"10.1016\/j.breast.2007.05.008_bib59","first-page":"5400","article-title":"ERBB-2(HER2\/neu) gene copy number, p185HER-2 overexpression, and intratumor heterogeneity in human breast cancer","volume":"55","author":"Szollosi","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/j.breast.2007.05.008_bib60","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ijc.2910580108","article-title":"Intratumoral heterogeneity for amplified genes in human breast carcinoma","volume":"58","author":"Lonn","year":"1994","journal-title":"Int J Cancer"},{"key":"10.1016\/j.breast.2007.05.008_bib61","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/modpathol.3800432","article-title":"Reliability of chromogenic in situ hybridization for detecting HER-2 gene status in breast cancer: comparison with fluorescence in situ hybridization and assessment of interobserver reproducibility","volume":"18","author":"Gong","year":"2005","journal-title":"Mod Pathol"},{"key":"10.1016\/j.breast.2007.05.008_bib62","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/1096-9896(200108)194:4<395::AID-PATH975>3.0.CO;2-4","article-title":"Are some breast carcinomas polyclonal origin","volume":"194","author":"Heim","year":"2001","journal-title":"J Pathol"},{"key":"10.1016\/j.breast.2007.05.008_bib63","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1097\/01.MP.0000086487.78558.7D","article-title":"Comparing fluorescence in situ hybridization and chromogenic in situ hybridization methods to determine the HER2\/neu status in primary breast carcinoma using tissue microarray","volume":"16","author":"Park","year":"2003","journal-title":"Mod Pathol"},{"key":"10.1016\/j.breast.2007.05.008_bib64","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1309\/P40P2EAD42PUKDMG","article-title":"Comparison of fluorescence and chromogenic in situ hybridization for detection of HER-2\/neu oncogene in breast cancer","volume":"119","author":"Gupta","year":"2003","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.breast.2007.05.008_bib65","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/modpathol.3880582","article-title":"Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma","volume":"15","author":"Zhao","year":"2002","journal-title":"Mod Pathol"},{"key":"10.1016\/j.breast.2007.05.008_bib66","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1097\/01.LAB.0000024360.48464.A4","article-title":"Chromogenic in situ hybridization: a novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma","volume":"82","author":"Dandachi","year":"2002","journal-title":"Lab Invest"},{"key":"10.1016\/j.breast.2007.05.008_bib67","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0002-9440(10)64785-2","article-title":"Chromogenic in situ hybridization: a practical alternative for fluoresence in situ hybridization to detect HER-2\/neu oncogene amplification in archival breast cancer samples","volume":"157","author":"Tanner","year":"2000","journal-title":"Am J Pathol"},{"key":"10.1016\/j.breast.2007.05.008_bib68","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1158\/1078-0432.CCR-0428-03","article-title":"Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization","volume":"10","author":"Isola","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2007.05.008_bib69","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1080\/00313020600561518","article-title":"Chromogenic in situ hybridization testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridization and immunohistochemistry","volume":"38","author":"Bilous","year":"2006","journal-title":"Pathology"},{"key":"10.1016\/j.breast.2007.05.008_bib70","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.breast.2005.09.008","article-title":"HER-2 gene amplification by chromogenic in situ hybridization (CISH) compared with fluoresence in situ hybridization (FISH) in breast cancer: a study of two hundred cases","volume":"15","author":"Saez","year":"2006","journal-title":"Breast"},{"issue":"Suppl 1","key":"10.1016\/j.breast.2007.05.008_bib71","first-page":"38A","article-title":"Evaluation of HER-2\/neu status in breast carcinomas: a combined approach including FISH, CISH, realtime QRT PCR and immunohistochemistry","volume":"18","author":"Kostopoulou","year":"2005","journal-title":"Mod Pathol"},{"key":"10.1016\/j.breast.2007.05.008_bib72","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1177\/106689690501300406","article-title":"Role of chromogenic in situ hibridization (CISH (TM)) in the evaluation of HER2 status in breast carcinoma: comparison with immunohistochemistry and FISH","volume":"13","author":"Li-Ning","year":"2005","journal-title":"Int J Surg Pathol"},{"key":"10.1016\/j.breast.2007.05.008_bib73","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/path.2022","article-title":"Dual-colour chromogenic in situ hybridization for testing of HER-2 oncogene amplification in archival breast tumors","volume":"210","author":"Laakso","year":"2006","journal-title":"J Pathol"},{"key":"10.1016\/j.breast.2007.05.008_bib74","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0002-9440(10)64377-5","article-title":"Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer","volume":"160","author":"Savinainen","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1016\/j.breast.2007.05.008_bib75","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/sj.bjc.6602029","article-title":"Clinical significance of Caveolin-1, Caveolin-2 and HER2\/neu mRNA expression in human breast cancer","volume":"91","author":"Sagara","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.breast.2007.05.008_bib76","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1158\/1535-7163.MCT-06-0129","article-title":"Correction for chromosome-17 is critical for the determination of true HER-2\/neu gene amplification status in breast cancer","volume":"5","author":"Dal Lago","year":"2006","journal-title":"Mol Cancer Ther"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977607001087?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977607001087?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:24:28Z","timestamp":1760775868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977607001087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":76,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["S0960977607001087"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2007.05.008","relation":{},"ISSN":["0960-9776"],"issn-type":[{"type":"print","value":"0960-9776"}],"subject":[],"published":{"date-parts":[[2007,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative evaluation of non-informative HER-2 immunoreactions (2+) in breast carcinomas with FISH, CISH and QRT-PCR","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2007.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}